Drug studied at 2 R.I. hospitals gains FDA approval for use in early Alzheimer’s diagnosis

PROVIDENCE – A drug studied at two Rhode Island hospitals has earned approval from the U.S. Food and Drug Administration for use in the early diagnosis of Alzheimer’s disease. Studies show that Tauvid, or flortaucipir F18, used along with positron emission tomography, or PET, imaging, helps detect the presence of a substance known as tau…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -